Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal
Johnson & Johnson agreed to acquire mental-illness drug developer Intra-Cellular Therapies for about $15 billion.
Cautious Optimism: Evaluating Johnson & Johnson’s Hold Rating Amid ITCI Acquisition Uncertainties
Wells Fargo analyst Larry Biegelsen has maintained their neutral stance on JNJ stock, giving a Hold rating yesterday.Stay Ahead of the ...
Johnson & Johnson makes $15 billion bet on mental-health drugs
Pharma giant Johnson & Johnson is buying Intra-Cellular Therapies, eying sales growth above analysts’ expectations through ...
Johnson & Johnson Could Serve As High-Yield Bond Alternative
Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest ...
MassDevice5d
Johnson & Johnson MedTech halts Varipulse PFA cases due to stroke reports
Johnson & Johnson MedTech has temporarily paused all U.S. external evaluations and cases using its Varipulse pulse field ...
Johnson & Johnson stock outperforms competitors despite losses on the day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Johnson & Johnson (JNJ) And Encourages Investors to Reach Out
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf ...